Keywords
How to Cite
Abstract
The placenta and fetal membranes have recently been proposed as an important stem cells source for regenerative medicine. Stem cells derived from amniotic membrane offer considerable advantages because of the ease of collection, their low immunogenicity and minimal ethical and legal barriers are associated with their use. Amnion-derived stem cells have also antitumoral properties. Hepatic failure is one of the major causes of morbidity and mortality and despite the development in therapies, hepatocarcinoma rates are high worldwide. The aim of this work was to study some aspects of cell death induced by the amniotic membrane conditioned medium (AM-CM) in hepatocarcinoma cells. We have analyzed the expression of proapoptotic proteins (Caspase-3, PARP-1) by qRT-PCR and Western blot, in HepG2 and HuH-7 cells treated with AM-CM. We have also analyzed p53 expression by immunofluorescence. We found a significant increment in Caspase-3 expression and in cleaved Caspase-3 and PARP-1, after 24 and 72 h of treatment with AM-CM in hepatocarcinoma cells. We have also observed that AM-CM significant increase p53 nuclear expression. Finally, we determined that AM-CM induced DNA fragmentation after 72 h of treatment in HepG2 cells. Our results begin positioning amnion-derived stem cells as emerging candidates in anticancer therapy.
Marks EI, Yee NS. Molecular Genetics and Targeted Therapy in Hepatocellular Carcinoma. Curr Cancer Drug Targets. 2015;16(1):53-70.
Niknejad H, Yazdanpanah G, Ahmadiani A. Induction of apoptosis, stimulation of cell-cycle arrest and inhibition of angiogenesis make human amnion-derived cells promising sources for cell therapy of cancer. Cell Tissue Res. 2016;363(3):599-608.
Magatti M, De Munari S, Vertua E, et al. Amniotic membrane-derived cells inhibit proliferation of cancer cell lines by inducing cell cycle arrest. J Cell Mol Med. 2012;16(9):2208-18.
Niknejad H, Khayat-Khoei M, Peirovi H, et al. Human amniotic epithelial cells induce apoptosis of cancer cells: a new anti-tumor therapeutic strategy. Cytotherapy. 2014;16(1):33-40.
This journal is registered under a Creative Commons Attribution 4.0 International Public License. Thus, this work may be reproduced, distributed, and publicly shared in digital format, as long as the names of the authors and Pontificia Universidad Javeriana are acknowledged. Others are allowed to quote, adapt, transform, auto-archive, republish, and create based on this material, for any purpose (even commercial ones), provided the authorship is duly acknowledged, a link to the original work is provided, and it is specified if changes have been made. Pontificia Universidad Javeriana does not hold the rights of published works and the authors are solely responsible for the contents of their works; they keep the moral, intellectual, privacy, and publicity rights.
Approving the intervention of the work (review, copy-editing, translation, layout) and the following outreach, are granted through an use license and not through an assignment of rights. This means the journal and Pontificia Universidad Javeriana cannot be held responsible for any ethical malpractice by the authors. As a consequence of the protection granted by the use license, the journal is not required to publish recantations or modify information already published, unless the errata stems from the editorial management process. Publishing contents in this journal does not generate royalties for contributors.